SCOTTSDALE, AZ--(Marketwired - November 03, 2016) - Lattice Biologics Ltd. (TSX VENTURE: LBL) (OTCBB: BLVKF) ("Lattice Biologics"), an emerging biotech leader in cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration, is pleased to announce two new agreements for sales and distribution of its AmnioVisc™ (minimally processed amniotic fluid supplement for the treatment of joint pain associated with osteoarthritis (OA) announced October 11, 2016). AmnioVisc™ will be produced by Lattice Biologics (the "Company") and will be distributed in the United States of America by OsteoArthritis Centers of America (OA Center) and Resilience.
"With approximately 27 million Americans currently affected by osteoarthritis, the market for high quality therapies, such as AmnioVisc™, is showing no signs of slowing down," shared Guy Cook, Lattice Biologics CEO.
He continued, "We are especially proud to offer patients a safe amniotic fluid which has proven to be effective. We anticipate this product will reward our investors by carving out a competitive advantage over the other treatments currently available for OA pain and subsequently accelerating revenue growth substantially."
OsteoArthritis Centers of America:
OsteoArthritis Centers of America® (OA Centers) features 140 locations across the United States, from coast to coast. OA Centers accredited clinics are exclusively licensed to offer the organization's proven, patented, non-surgical, FDA approved treatments for chronic pain in knees, hips, shoulders, and back. These procedures are covered by Medicare and most insurance plans. The Combinatorial Therapy For Treatment of Osteo arthritis of the Knee Program (OA Knee Program) protocol has been used to successfully treat more than 30,000 patients to date. Published studies show that the Program works and the treatments are covered by most insurances and Medic are. With its focus on OA patients, this group is an ideal fit for AmnioVisc™ distribution, empowering countless new patients with access to this proven treatment.
OA Centers is owned by Rehab Management Group Inc. (RMG), a team of dedicated healthcare business professionals, physicians, and technicians. RMG offers expertise in developing results-oriented clinic al services that have been accepted as the gold standard of care by many companies, including pain management practices, primary care physicians, orthopedic practices, endocrinologists and others who treat neuropathic and neuromuscular disease.
"Osteo Arthritis Centers of America is very excited to add AmnioVisc™ to our product offering, giving our affiliated physicians access to cutting edge treatments," commented William Feley, President of RMG.
"We are also very pleased," added Feley, "to introduce a human amnio viscosupplement to our portfolio as a natural and effective added solution for our osteoarthritis patients that can be offered at competitive prices."
Building on Lattice Biologics' October 31, 2016 announcement of its partnership with AllianceMed, LLC (third-party medical revenue generating company) to support insurance reimbursement for the Company's AmnioVisc™ joint pain treatment and make it available to more patients, comes notice of a new agreement with Resilience, a national medical implant and biologic supplier.
Resilience provides a pathway to regenerative medicine, utilizing placental tissue minimally manipulated allografts. These tissues contain many factors needed for wound healing, such as collagen, growth factors, amnio acids, carbohydrates, cytokines, cryo-fractured amniotic membrane and extra cellular matrix (ECM).
Resilience will provide distribution services, bringing AmnioVisc™ to medical practices across the country, and AllianceMed will manage insurance billing activities, smoothing the revenue process for physicians and eliminating the reimbursement challenges of utilizing a modern biologic product. Combining in-depth product knowledge with insurance support, Resilience offers comprehensive support for physicians who want to share the regenerative medicine benefits of Lattice's novel amnio viscosupplement with their patients. As a large dedicated distributor, Resilience serves physician relationships nationwide and maintains additional distribution partnerships in Arizona, California, Nevada, Colorado, New Mexico, Texas, Oklahoma, and Georgia.
Resilience Co-President and Co-Founder, Matt Perez shared, "At Resilience, our goal is to match up medical practices with the ideal clinical products and technologies for their needs. We are constantly working to get novel biologics, such as AmnioVisc™, into the hands of the physicians who are looking for these innovative techniques."
"Resilience is especially passionate," Perez continued, "about making regenerative medicine available to physicians who would otherwise expect to be blocked by cost restraints. Utilizing a streamlined insurance billing and reimbursement program makes this possible and offers a great advantage."
"As illustrated by AmnioVisc™'s incredible results, we always confirm that products offer great clinical performance and make sure that they will bring overall value to practices before initiating distribution."
LOGISTICS SOLUTION FOR THE HIGHEST PRODUCT QUALITY, SAFETY AND EASE OF USE:
In addition to the above distribution agreements, Lattice Biologics is pleased to announce it has selected Cryoport, Inc. (NASDAQ: CYRX) (NASDAQ: CYRXW) ("Cryoport"), the world's leading cryogenic logistics company dedicated to the life sciences, as its exclusive logistics solution for AmnioVisc™, amnio viscosupplement for joint pain relief.
Because AmnioVisc™ is derived from healthy scheduled caesarean procedures, Lattice Biologics carefully researched many different shipping options to identify a logistics solution that would treat amnion delivery with the same appreciation and respect that the Company maintains for all its valuable natural biologic products. Cryoport meets Lattice's stringent quality and safety requirements and offers a 24/7 real time electronic monitoring system that provides continuous feedback during the entire logistics process for the ultimate in accountability and reliability for providers.
Cryoport has provided essential assistance for the AmnioVisc™ launch, including the necessary international paperwork and logistics support, including the ability to intervene when necessary, to prevent package delays in transit.
How it Works:
To increase transport and storage life, minimize the risk of temperature deviation, and ensure unmatched safety, AmnioVisc™ is shipped via Cryoport's signature Cryoport Express® Dry Vapor Shippers, the market's most advanced storage and shipping units. (Cryoport's cryyogenic storage dewars are a specialized type of vacuum flask used for storing cryogens (in this case, liquid nitrogen) which has boiling points are much lower than room temperature, minus 196 degrees Celcius.) The Cryoport Express® Shipper is a scientifically engineered logistics unit embracing its dewars, Smart Pack II Condition Monitoring system, and highly engineered packaging, built to protect contents. It is constructed to ensure that even the most temperature-sensitive materials can be shipped and stored safely and with certainty.
Cryoport's lightweight and reusable Cryoport Express® Shippers feature a combination of advanced packaging, cryogenics and high-vacuum technology. It's dewars are composed of aircraft-grade aluminum protecting an inner holding chamber. The inner chamber is surrounded by a high-surface, low-density open cell plastic foam that allows for hold times of up to 10 days. This design ensures that the liquid nitrogen remains within the foam and that the specimen cylinder stays dry, regardless of the dewar's orientation. (www.Cryoport.com)
Cutting-Edge Logistics Advantages:
The Cryoport Express® Shipper solution features AmnioVisc vials shipped in dry vapor liquid nitrogen instead of liquid state liquid nitrogen, which eliminates the risk of splashing in the container, making it safer and easier to transport and handle. With internal temperatures of approximately -196°C in the vapor phase, Lattice can preserve the vials for up to 10 days as compared to the relatively short 2-3 day duration guaranteed by a would-be competitor. The Cryoport team has even taken the extra step to provide every customer with a step-by-step instruction booklet including pictures illustrating how to load and unload the AmnioVisc™ vials form the container. Physicians will appreciate the simplicity of this shipping system and the easy container return process.
Learn More AmnioVisc™ and Order:
Armed with six months of excellent results from a 275-patient study to assess its efficacy and safety, AmnioVisc™ is the most studied amnio viscosupplement to date. In a controlled study, it demonstrated lasting safe pain relief and far fewer adverse effects than the current standard of care Hyaluronic Acid (HA) viscosupplements on the market1.
AmnioVisc™ is a novel, targeted regenerative therapeutic that is delivering promising relief for patients suffering from all degrees of OA pain and can be used to treat knee, elbow, shoulder, wrist, foot, ankle, neck, and spinal joints. Amniotic fluid has been proven to be significantly more effective than traditional viscosupplements, such as those from animal sources or fermentation1.
Lattice Biologics Ltd. offers AmnioVisc™ in 0.5ml, 1.0ml, 2.0ml, 2.5ml, and 4.0ml sized doses. AmnioVisc™ is currently patent pending and available for distribution throughout the United States, Canada, and internationally.
For samples, order, or more information about AmnioVisc™, please contact: Clinicals@LatticeBiologics.com | call toll-free: 1-855-286-8088
1Read the study's clinical research here.
Lattice Biologics Ltd.
Chief Executive Officer
Telephone No: (480) 563-0800
About Lattice Biologics Ltd.:
Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.
Versatile allografts for a variety of surgical applications:
- Enhancing fusion in spine surgery
- Enhancing breast reconstruction post mastectomy for breast cancer patients
- Sports medicine indications, including ACL repair
- Promotion of bone regeneration in foot and ankle surgery
- Promotion of cranial healing following neurosurgery
- Enhancing wound repair in burn victims
- Subchondral bone defect repair in knee and other joint surgeries
The Company is currently exploring new technologies in regenerative and personalized medicine:
Lattice Biologics operates headquarters, laboratory and manufacturing facilities in Scottsdale, Arizona as well as offices in Toronto Ontario. The Company maintains all necessary licensures to process and sell its tissue engineered products within the U.S. and internationally. This includes Certificates to Foreign Governments from the U.S. Food and Drug Administration (FDA) and registrations for 29 countries, which allow the export of bone, tendon, meniscus, ligament, soft tissue, and cartilage products outside of the U.S.
Lattice Biologics (TSX VENTURE: LBL) (OTCBB: BLVKF) became a publicly traded company on January 4, 2016.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Statement on Forward-Looking Information:
Certain information contained in this news release constitutes "forward-looking statements" within the meaning of the 'safe harbour' provisions of Canadian securities laws. All statements herein, other than statements of historical fact, are to be considered forward looking. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "potential", "future", "expected", "could", "possible", "goal", "intends", "will" or similar expressions. Forward-looking statements in this news release include, without limitation: information pertaining to the Company's strategy, plans, or future financial performance. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Lattice to be materially different from those expressed or implied by such forward-looking statements.
Forward-looking statements are necessarily based upon a number of factors and assumptions that, while considered reasonable by management as of the date such statements are made, are inherently subject to significant business, economic and competitive uncertainties and contingencies. The factors and assumptions that could prove to be incorrect, include, but are not limited to: that market prices will be consistent with expectations, the continued availability of capital and financing, and that general economic, market and business conditions will be consistent with expectations. The forward-looking statements are not guarantees of future performance. We disclaim any obligation to update or revise any forward-looking statements, except as required by law. Readers are cautioned not to put undue reliance on these forward-looking statements.
United States Advisory: The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the U.S. Securities Act) unless an exemption from the registration requirements of the U.S. Securities Act is available. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.
Subscribe to Lattice News Updates
Follow us on Twitter: @LatticeBio
Image Available: http://www.marketwire.com/library/MwGo/2016/11/3/11G120682/Images/3_part_announcement_graphic_800_458-0a0f331108bd9708ae23e38e9d11b8f7.jpg